Novel Therapeutic Medications for Venous Thromboembolism Prevention in Trauma Patients: Findings From the Consensus Conference to Implement Optimal Venous Thromboembolism Prophylaxis in Trauma

Authors

Navpreet K Dhillon
Elliott R Haut
Michelle A Price
Todd W Costantini
Amanda L Teichman
Bryan A Cotton
Eric J Ley

Publication Date

3-1-2023

Journal

The Journal of Trauma and Acute Care Surgery

Abstract

Trauma patients are at high risk for venous thromboembolism (VTE). Despite evidence-based guidelines and concerted efforts in trauma centers to implement optimal chemoprophylaxis strategies, VTE remains a frequent diagnosis in trauma patients. Current chemoprophylaxis strategies largely focus on the subcutaneous injection of low-molecular-weight heparin, which is administered twice daily. Novel approaches to pharmacologic VTE prophylaxis have the potential to reduce VTE rates by improving patient compliance through oral administration or through their ability to target alternative pathways that mediate thrombosis. While novel pharmacologic VTE prophylaxis strategies have been studied in nontrauma patients, there is a paucity of literature in trauma patients where the risk of thrombosis versus hemorrhage must be carefully considered. As a component of the 2022 Consensus Conference to Implement Optimal VTE Prophylaxis in Trauma, this review provides an update of the novel chemoprophylaxis agents for potential use in trauma patients. Here, we will consider the relative risks and benefits related to the use of these drugs, evaluate the current literature in nontrauma patients, and consider future directions that could potentially improve posttrauma VTE prophylaxis.

Keywords

Humans, Venous Thromboembolism, Anticoagulants, Heparin, Low-Molecular-Weight, Hemorrhage, Risk

DOI

10.1097/TA.0000000000003853

PMID

36729880

PMCID

PMC9974825

PubMedCentral® Posted Date

3-1-2024

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes